Biontech $BNTX (+1,95%) has high hopes for its new drug candidate BNT327, which is being developed for the treatment of advanced cancer. This innovative approach aims to combat the tumor-related effects that weaken the body's own immune system. The acquisition of the Chinese company Biotheus secured Biontech the worldwide rights to this promising drug. But while the future looks promising, the Mainz-based company is facing a significant net loss of around 700 million euros in 2024. This continues the decline that began with the declining business around the Covid-19 vaccine. In 2022, Biontech was still able to record a profit of around 9.4 billion euros, but in 2023 this fell dramatically to only around 930 million euros. This is a clear indication that the company is in a transition phase and needs to develop new strategies to get back on the road to success.
In Germany, Volkswagen $VOW (+1%) is providing positive news for its employees: they can look forward to uncapped bonuses this year! Despite an ongoing austerity program and an agreement with IG Metall, which temporarily suspends profit sharing from 2026, the bonus for 2024 remains unaffected. Head of the Works Council Daniela Cavallo announced at the last works meeting that the bonus will continue to be paid in full. However, the exact amount of the bonus is still unclear, as it depends on the previous year's profit, which is to be published on March 11. Volkswagen has revised its profit forecast for 2024 downwards several times in recent months and now expects an operating profit of 18 billion euros. Despite the uncertainties and challenges, the company remains committed not only to supporting its employees, but also to keeping their motivation high.
Sources: